CRL
Charles River Laboratories International, Inc.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$289.07
−1.46%Forward multiples
Based on analyst estimates
- P/E forward
- 23.47x
- P/E 2026E
- 25.59x
- P/E 2027E
- 22.75x
- P/E 2028E
- 20.47x
- P/S forward
- 3.54x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 4.86x
- Price / sales
- 3.45x
- Price / cash flow
- 23.71x
Enterprise value
- Enterprise value
- $16.6B
- EV / sales
- 4.16x
- EV / EBITDA
- 75.48x
- EV / EBIT
- 33.70x
- Market cap
- $13.8B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026